Homepage Top Section2

As per the deal announced in December 2019, Charles River Laboratories offered to buy HemaCare for $25.40 per share. The California-based company, which will now operate under Charles

Under the terms of the transaction agreement, GSK has received an upfront payment of €308m ($345m) and Bavarian Nordic is expected to pay a total of up to

The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9-4 in favour of approving Keytruda for the new indication. The anti-PD-1 therapy has already been approved in the US

HemaCare has expertise in the customisation of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. HemaCare provides a range of human

The company has unveiled the topline results from its global phase 111 Luster-1 and Luster-2 studies evaluating the efficacy and safety of the investigational oral, once-daily, DP2 receptor

According to 3M, the total consideration includes cash, an interest-bearing security, and a 17% non-controlling stake in the new company that will hold the divested drug delivery business.

According to the US biopharma company, lebrikizumab is a monoclonal antibody that can bind with very high affinity with the Interleukin 13 (IL-13) cykotine. Through this mechanism, the

Headquartered in California, Synthorx is focused on developing therapies for cancer and autoimmune disorders. Sanofi is offering to buy the biotechnology company at $68 per share. THOR-707, the